Department of Emergency, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China.
Department of Haematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China.
Oncol Rep. 2020 Aug;44(2):543-554. doi: 10.3892/or.2020.7627. Epub 2020 May 28.
Changes in histone H3 lysine 9 trimethylation (H3K9me3) may be related to the development of drug‑resistant acute myeloid leukaemia (AML); insights into the network of H3K9me3 may improve patient prognosis. Patient data were derived from the Gene Expression Omnibus (GEO) database and data from AML cells treated with chidamide, a novel benzamide chemical class of histone deacetylase inhibitor (HDACi), in vitro were derived from ChIP‑seq. Patients and AML cell data were analysed using GEO2R, GOseq, KOBAS, the STRING database and Cytoscape 3.5.1. We identified several genes related to the upregulation or downregulation of H3K9me3 in AML patients; some of these genes were related to apoptosis, autophagy, and the pathway of cell longevity. AML cells treated with chidamide in vitro showed the same gene changes. The protein interactions in the network did not have significantly more interactions than expected, suggesting the need for more research to identify these interactions. One compelling result from the protein interaction study was that sirtuin 1 (SIRT1) may have an indirect interaction with lysine‑specific demethylase 4A (KDM4A). These results help explain alterations of H3K9me3 in AML that may direct further studies aimed at improving patient prognosis. These results may also provide a basis for chidamide as a treatment strategy for AML patients in the future.
组蛋白 H3 赖氨酸 9 三甲基化 (H3K9me3) 的变化可能与耐药性急性髓系白血病 (AML) 的发展有关;对 H3K9me3 网络的深入了解可能会改善患者的预后。患者数据来自基因表达综合数据库 (GEO),体外用新型苯甲酰胺类组蛋白去乙酰化酶抑制剂 (HDACi) 西达本胺处理的 AML 细胞的数据来自 ChIP-seq。使用 GEO2R、GOseq、KOBAS、STRING 数据库和 Cytoscape 3.5.1 分析患者和 AML 细胞数据。我们鉴定了一些与 AML 患者 H3K9me3 上调或下调相关的基因;其中一些基因与细胞凋亡、自噬和细胞长寿途径有关。体外用西达本胺处理的 AML 细胞也表现出相同的基因变化。网络中的蛋白质相互作用没有比预期的更多,这表明需要进一步研究来识别这些相互作用。蛋白质相互作用研究的一个引人注目的结果是,沉默信息调节因子 1 (SIRT1) 可能与赖氨酸特异性去甲基酶 4A (KDM4A) 存在间接相互作用。这些结果有助于解释 AML 中 H3K9me3 的改变,这可能指导进一步的研究,以改善患者的预后。这些结果也可能为西达本胺作为未来 AML 患者的治疗策略提供依据。